Neudle.com: "multiple sclerosis clinical patterns"

Differential
(Click to cross reference)

abdominal cramps

abdominal reflex, absent

abortion, spontaneous

abscess, intracerebral

abscess, intracranial-fungal

abscess, lung

acute disseminated encephalomyelitis

acute disseminated encephalomyelitis, multiphasic

adenylate kinase 5 autoantibodies

advances in neurology

adverse drug reaction

alternating rapid movement

alveolar hypoventilation

Alzheimer's disease

amnesia

amnesia, anterograde

amphiphysin antibodies

amygdala

amyotrophic lateral sclerosis

amyotrophic lateral sclerosis, familial

amyotrophic lateral sclerosis, prognosis

angiotensin-converting enzyme

antibodies to measles

antibodies to myelin basic protein

antibodies to myelin oligodendrocyte glycoprotein

antihistamines

antimyelin antibodies

arteriovenous malformation

autoimmune cerebellar ataxia

autoimmune disease

autonomic dysfunction

B cell lymphocyte depletion

B cell lymphocytes

bacterial infection

bacterial infection, CNS

Barkhof MR criteria for MS

basal ganglia

basal ganglia, infarction

basal ganglia, lesion of

basal ganglia, lesion, bilateral

bone marrow infarction

bone marrow necrosis

bone marrow suppression

bone marrow transplantation

Borrelia burgdorferi infection

brachial neuritis

brachial plexus neuropathy

brain biopsy, indication

brainstem

brainstem, atrophy

brainstem, infarction of

CAT scan, disappearing lesion on

CAT scan, emission

CAT scan, emission, abnormal

CAT scan, pelvis

caudate nucleus

caudate nucleus, atrophy

cavernous sinus

cavernous sinus, expansion

cavernous sinus, lesion of

central nervous system, infection of

cerebellar atrophy, secondary

cerebellar degeneration

cerebellar lesion

cerebellar peduncle

cerebral autosomal dominate arteriopathy with subcortical infarction and leukoencephalopathy

cerebral cortex

cerebral cortical atrophy

cerebral edema

cerebral edema, vasogenic

cerebral embolism

cerebral infarction

cerebral infarction, small, deep

cerebral infarction, subcortical

cerebrospinal fluid

cerebrospinal fluid, abnormal

cerebrospinal fluid, cell count

cerebrospinal fluid, cytology

cerebrospinal fluid, elevated protein of

cerebrospinal fluid, gammaglobulin of

cerebrospinal fluid, gold sol.curve of

cerebrospinal fluid, oligoclonal bands, absent

cerebrospinal fluid, oligoclonal IgG in

cerebrospinal fluid, oligoclonal IgM in

cerebrospinal fluid, protein of

cerebrospinal fluid, proteincytologic dissociation

cerebrospinal fluid, xanthochromia of

cerebrovascular accident

cerebrovascular accident, familial occurrence

cerebrovascular accident, mimics

cerebrovascular accident, multiple

cerebrovascular accident, nonvascular territory

cerebrovascular accident, recurrent

cerebrovascular accident, young adult

cerebrovascular disease, cardiovascular disease with

chest x-ray

chest x-ray, abnormal

Clinical Pathologic Conference(C.P.C.)

clinicoradiologic dissociation

cognition

collapsin response mediator protein 5 IgG

congestive heart failure

contactin associated protein like 2 antibodies

controversies in neurology

conversion reaction

cop 1

corpus callosum, atrophy of

corpus callosum, lesion of

cortical blindness

cost effectiveness

cranial nerve palsies

cranial neuropathy

cranial neuropathy, multiple

C-reactive protein, elevated

creatine phosphokinase(CPK)elevated

cryptococcoma, cerebral

dementia, rapidly progressive

demyelinating disease

differential diagnosis

diplopia

disability rating scale, neurological

disability, neurological

disease modifying agents

disorientation

dizziness

drowsiness

drug induced neurologic disorders

dysarthria

dysdiadochokinesia

dyskinesia

dyskinesia, buccal lingual facial

dysmetria

echocardiogram

efficacy

electrocardiogram, abnormal

electroencephalogram

electroencephalogram, abnormalities of

electroencephalogram, focal delta activity

electroencephalogram, periodic complexes

ELISA

embolism, fat

encephalitis

encephalitis, autoimmune

encephalitis, brainstem

encephalitis, focal

encephalitis, paraneoplastic

encephalitis, Rasmussen's

encephalitis, recurrent

encephalitis, viral

encephalomyelitis

encephalomyelitis, postinfectious

encephalopathy

epidemiology of neurology

episodic disorders

episodic neurologic deficits

erythema migrans

EVIDENCE trial

evidence-based research

evoked potentials

eye movement, disorders of

Fabry's disease

facial nerve palsy

facial nerve palsy, bilateral

facial nerve palsy, recurrent

facial pain

facial weakness

facial weakness, bilateral

fluorescein angiography

fungal infection, CNS

gammaglobulin therapy, intravenous

gastrointestinal perforation

gender

gene mutation

genetic neurologic disorders

genetic testing

glioma

glutamic acid decarboxylase, antibody

granular osmiphilic material

granulomatosis with polyangiitis

granulomatous disease

gray matter

grimacing

Guillain Barre syndrome

hallucination

hallucination, visual

hemianopia, transient

hemifacial atrophy

hemimyoclonic jerks

hemiparesis

hemiparesis, transient

hemiplegia

hemoglobin abnormality, neurologic complications of

hepatosplenomegaly

heralding manifestation

herniated disc, lumbar-laminectomy

herpes simplex encephalitis

herpes simplex encephalitis, diagnosis of

herpes virus

herpes virus infection

herpes zoster

herpes zoster, disseminated

hip pain

hippocampal atrophy

hippocampus

hippocampus, hyperintense

HLA

human herpesvirus 6

hydrocephalus, exvacuo

hypersomnia

hypertension

hypertrophic intracranial pachymeningitis

hypertrophic pachymeningitis, IgG4 related disease

hypertrophic spinal pachymeningitis

hypogonadism

hyponatremia

hypopigmentation of skin

hypothalamus, lesion of

iatrogenic neurologic disorders

idiopathic thrombocytopenic purpura

IgG4-related disease

immunization, neurologic complications with

immunohistochemistry

immunologic disease

immunology and the nervous system

immunomodulation

immunosuppression

immunosuppressive agents

immunotherapy

in vitro fertilisation

incidence

inclusion bodies

inclusion bodies, eosinophilic cytoplasmic

inclusion bodies, eosinophilic intranuclear

inclusion bodies, intranuclear

infection

influenza immunization

intellectual deficit

intellectual deterioration

iron, serum, elevated

jaw pain

JC virus

lactic acidemia

lactic dehydrogenase(LDH)

laminectomy, lumbar

laquinimod

lesions too numerous to count

leucine rich glioma inactivated 1 antibodies

leukoencephalitis

leukoencephalopathy

leukopenia

level of consciousness

level of consciousness, decreased

life expectancy

limbic encephalitis

linomide

lipid storage disorder of CNS

liver function enzymes

lobar atrophy

long bone lesion

low back pain

lumbosacral plexopathy

lumbosacral plexus

lumbosacral plexus, neuritis

lung biopsy

Lyme disease

lymphadenopathy

lymphadenopathy, hilar

lymphopenia

malformation, vascular

malignancy screen

malignancy, occult

Marburg's disease

McDonald criteria for MS

mediastinum, lymph-node biopsy

mediastinum, mass of

medication withdrawal

medulla oblongata, lesion of

MELAS syndrome

memory, defect of recent

memory, impairment of

meningeal biopsy

meningeal enhancement

meningismus

meningitis

meningitis, aseptic

meningitis, carcinomatous

meningitis, granulomatous

meningitis, syphilitic

meningoencephalitis

mental status, abnormal

meralgia paresthetica

mesial temporal lobe

methotrexate

microangiopathy, brain

microangiopathy, retina

midbrain, lesion of

middle cerebellar peduncle, lesion

mitochondrial disease

mitoxantrone

monoclonal antibodies

monoclonal gammopathy

mononeuropathy

mononeuropathy multiplex

MRI, contrast enhanced

MRI, contrast enhanced, delayed

MRI, contrast enhanced, high dose

MRI, demyelinating disease

MRI, diffusion tensor

MRI, diffusion weighted

MRI, disappearing lesion on

MRI, false negative

MRI, FLAIR

MRI, high signal foci on

MRI, hypointense signal foci on

MRI, lesion burden

MRI, magnetization transfer sequence

MRI, spinal cord, increased intramedullary cord signal

MRI, spine

MRI, starfield pattern

MRI, volumetry

MRS

multiple sclerosis

multiple sclerosis, acute

multiple sclerosis, aggressive

multiple sclerosis, asymptomatic

multiple sclerosis, benign form of

multiple sclerosis, children

multiple sclerosis, chronic progressive

multiple sclerosis, clinical patterns

multiple sclerosis, conversion to clinically definite

multiple sclerosis, cost of

multiple sclerosis, diagnosis of

multiple sclerosis, diagnostic criteria

multiple sclerosis, differential diagnosis of

multiple sclerosis, disability status scale

multiple sclerosis, disease activity

multiple sclerosis, etiology of

multiple sclerosis, familial

multiple sclerosis, misdiagnosis

multiple sclerosis, monosymptomatic

multiple sclerosis, pathogenesis

multiple sclerosis, plaque

multiple sclerosis, presenting manifestations

multiple sclerosis, prognosis

multiple sclerosis, prophylaxsis

multiple sclerosis, relapsing

multiple sclerosis, risk factors for

multiple sclerosis, secondary progressive

multiple sclerosis, treatment of

multiple sclerosis, treatment of, first attack

multiple sclerosis, without CSF bands

multiple sclerosis, worsening

muscle pain

myasthenia gravis

myasthenia gravis, paraneoplastic

myasthenic syndrome

myelin basic protein

myelitis

myelitis, longitudinal

myelitis, transverse

myeloma, osteosclerotic

myelomalacia

myelopathy

myelopathy, chronic progressive

myocardial infarction

natalizumab, discontinuation

nausea and vomiting

negative

neoplasm, primary intracerebral

neoplasm, primary of CNS

nerve conduction studies

neuroendocrinology

neurofibrillary degeneration

neurologic complications of, systemic disease

neurologic disease

neurologic disease, diagnoses of

neurologic disease, multifocal

neurologic examination

neurologic practice

neurologic signs

neurologic symptoms

neuromuscular junction

neuromyelitis optica (Devic's disease)

neuromyelitis optica spectrum disorder

neuronal cell surface antigen

neuronopathy, sensory

neuropathology

neuropathy

neuropathy, painful

neuropathy, paraneoplastic

neuropathy, peripheral, treatment

neuropathy, sensory

neuroprotective agents

neurosyphilis

neurotoxic

neutralizing antibodies

nonsteroidal anti-inflammatory drug

normal

Notch3 gene

nystagmus

nystagmus, primary position of gaze

nystagmus, vertical

occipital lobe, infarction

ocrelizumab

ocular dipping

ofatumumab

onconeural antibodies

ophthalmoplegia

opportunistic infection

opportunistic infection, CNS

opsoclonus

opsoclonus-myoclonus syndrome

optic atrophy

optic chiasm

optic chiasm, lesion of

optic neuritis

optic neuritis, bilateral

optic neuritis, recurrent

optic neuropathy

optic neuropathy, bilateral

orchitis

organomegaly

pachymeningitis, cranial

paraneoplastic cerebellar degeneration

PAS positive material in the brain

patient information and support

periaqueductal lesion

periarteritis nodosa

pericarditis

peripheral nerve, lesion of

pleocytosis of cerebrospinal fluid

pleurisy

POEMS syndrome

polymerase chain reaction

polyneuropathy

polyneuropathy, chronic inflammatory demyelinating

posterior cerebral artery territory infarction

postpartum

potassium channel antibodies

practice guidelines

precipitating factors

pregnancy, neurologic complications in

prevention of neurologic disorders

prognosis

progressive hemifacial atrophy

progressive multifocal leucoencephalopathy

progressive neurologic disorder

prosopagnosia

psychiatric problems in neurologic disorders

psychological testing

psychotic behavior

pulmonary edema

pulmonary infiltrates

pupil

pupil, abnormality in neurologic disorders

pursuit eye movements, abnormal

rapidly progressing neurologic illness

rash

reading disorder, acquired

ReBUILD study

recurrent

Red flags

rehabilitation for neurologic disorders

release phenomena

remote effect of cancer on the nervous system

remyelination

renal failure

respiratory failure

reticular activating system

retinal branch artery occlusion

retinopathy

reversible neurologic disorder

review article

rheumatoid arthritis factor(R.A.factor)

risk factors

risk stratification

risk-benefit assessment

rituximab

Romberg's sign

rubeola virus

saccadic eye movements, abnormal

safety

salivation, excessive

scleroderma, neurologic involvement with

sclerosis, bone

scotoma

screening

sedimentation rate, elevated

seizure

seizure, focal

seizure, intractable

seizure, psychomotor-temporal lobe

sensorineural hearing loss

serologic testing

serologic testing of cerebrospinal fluid

seronegative

serum glutamic oxaloacetic transaminase

Sjogren's syndrome, neurologic manifestations of

skin, lesions in neurologic disorders

small vessel disease

somnolence

spinal cord

spinal cord, compression of

spinal cord, enlargement

spinal cord, lesion of

spinal cord, vascular malformation of

spinal pachymeningitis

spinal stenosis

spinal stenosis, cervical canal

spirochete infection

splenomegaly

spontaneous remission

standing difficulty

statin therapy

stem cell transplantation

steroid

steroid therapy, CNS treatment and complications with

stress, emotional

strokelike episodes

subacute sclerosing panencephalitis(S.S.P.E.)Dawson's disease

subacute sclerosing panencephalitis, adult onset

Susac's syndrome

sweating

symmetric brain lesions

syphilis, diagnosis and treatment

syphilis, neurologic complications with

temporal artery, biopsy

temporal lobe

temporal lobe, lesion

temporal lobe, lesion, bilateral

third ventricle, enlargement of

transient neurologic deficit

trauma

treatment of neurologic disorder

tremor

tremor, intention

trigeminal neuropathy

tumor necrosis factor

tumor necrosis factor inhibitor

ulcerative colitis

unconsciousness

upward deviation of eyes

uremia

urinary tract infection

vaccination, neurologic complications with

vaccine

vascular endothelial growth factor

vasculitides

vasculopathy

ventricular enlargement

vertigo

viral infection

viral infection, CNS

viral infection, reactivation

vision, blurred

visual acuity

visual evoked response

visual loss

visual loss, sudden

visual loss, transient

visuospatial disturbance

walking, difficulty with

war

water channel antibodies

weakness

weakness, generalized

weight loss

Western immunoblot test

wheelchair

white matter disease

white matter, dirty-appearing

Showing articles 0 to 50 of 8988 Next >>

Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 387:1022-1032, Case 28-2022, 2022

Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020

Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020

Diagnostic Tools for Immune Causes of Encephalitis
Clin Microbiol Infect 25:431-436, Lascano, A.M.,et al, 2019

Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018

Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018

Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018

Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017

Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017

Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017

Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017

Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017

Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017

Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015

Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015

Marburgs Variant of Multiple Sclerosis with Extensive Brain Lesions
Int J Neurol Neurother doi:10.23937/2378-3001/2/1/1027, Ludwig, A.,et al, 2015

Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014

CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapsing-Remitting MS
Neurol 83:1780-1788, Limmroth, V.,et al, 2014

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

IgG4-Related Hypertrophic Pachymeningitis
JAMA Neurol 71:785-793, Lu, L.X.,et al, 2014

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014

Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Subacute Sclerosing Panencephalitis
Adams & Victors Principles of Neurology, Chp 33, pg 766, Ropper, A.H.,et al, 2014

Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Clinicopathologic Conference, Blind and Confused, Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 70:932-936, Sharma, V.,et al, 2013

Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013

Subacute Sclerosing Panencephalitis
www.MedLink.com, February, Auwaeter,P.G.&Johnson,R.T., 2013

Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012

Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012

Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012

Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011

Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011

Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011

When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Showing articles 0 to 50 of 8988 Next >>